Maciej Banach

Lodz, Poland

Prof. Maciej Banach was an Undersecretary of State at the Ministry of Science and Higher Education of the Republic of Poland (2010-2012). He is a President of Polish Mother’s Memorial Hospital – Research Institute (PMMHRI) (February 2014-), Head of Cardiovascular Research Centre at University of Zielona Gora, full Professor of Cardiology at the Medical University of Lodz (MUL) and PMMHRI, Head of Foreign Affairs Office (2012-2014), Head of Department of Hypertension (2008-) at the Medical University of Lodz and Professor in the Department of Nephrology, Hypertension and Family Medicine, Chair of Nephrology and Hypertension, at the WAM University Hospital in Lodz, Poland (2009-).

He is member of the Executive Committee of European Atherosclerosis Society (EAS) working as an Advisor in Matters related to European Union Relations/Contacts, and the International Atherosclerosis Society (IAS) Regional Federation Executive Committee Member for Europe. He is a Founder and Head of the Polish Lipid Association (PoLA) (2011-) – the official partner of National Lipid Association (NLA, US) and Lodz Chapter of Polish Society of Hypertension (2009-). He is the founder of the Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group (2012-) – a group of over 150 worldwide experts aimed to investigate the most important issues in the field of lipid disorders, hypertension, nutrition and cardiovascular risk, as well as the International Lipid Expert Panel (ILEP) (2015-), which has been founded to prepare recommendations in the area of preventive cardiology in the most debatable issues that have not been covered in the existing guidelines. He is a member of 2 largest worldwide databases – the Global Burden of Disease (GDB) (University of Washington, Seattle, US) and Non-Communicable Diseases Risk Factor Collaboration (NCD-RisC, Imperial College of London, UK). He is also Founder and President of the foundation – Think-Tank “Innovation for Health”, which gathers six main health research institutes and over 40 medical business representatives in Poland with main aim to make innovations in the medical area in Poland. He is a Visiting Professor of University of Alabama at Birmingham (UAB) and University of Medicine and Pharmacy Victor Babes in Timisoara, Romania (2014-). 

Prof. Banach has published over 750 original articles, reviews, editorials and book chapters in the field of hypertension, dyslipidemia, cardiology, cardiac surgery, and risk stratification (622 acc. to PubMed, 706 acc. to Web of Knowledge/Publons, 553 acc. to SCOPUS, 766 acc. to ResearchGate – RG Score: 52.19, and 1020 acc. to Google Scholar). His combined IF (for only full-text manuscripts) is over 7000 pts., number of citations: 10,055 (acc. Web of Science Core Collection), 11,026 (acc. SCOPUS), 10,651 (acc. ResearchGate), and 16,027 (acc. Google Scholar), Hirsch’s Index = 45 (WoS/Publons), 47 (SCOPUS), 48 (ResearchGate) and 58 (i10-index: 330) (Google Scholar) – being within 1% the highest cited scientists in the world (in the research area of Clinical Medicine and Pharmacology and Toxicology) according to Essential Science Indicators by Clarivate (with 22 TOP Papers). Prof. Banach is also within top 10 worldwide experts according to ExpertScape in the field of statin therapy (7), cholesterol (13), and HDL cholesterol (10).

He is a laureate of several prizes and award, including: Doctor Honoris Causa of the Institute of Cardiology in Kiev (2018), and the University of Medicine and Pharmacy Victor Babes in Timisoara (2017); Gold Honorary Medal for scientific achievements of the Medical Faculty of Medical University in Kosice, Slovak Republic (2018), The Manager of the Year 2016 – Public Entities (2017), “Gold Scalpel” Distinction in 2016 for the Innovation; The Personality of the Year 2013 in Poland for the development of science in the field of healthcare – founded by the Heath Manager journal (Termedia Publishing House), Super-Talent in Medicine 2012 Award – the winner of the competition for young scientists in medicine (up to 40) founded by Puls Medycyny journal; scientific awards of Ministry of Health of Republic of Poland for the cycle of publications (2009, 2011), 18 individual and group scientific awards of President of Medical University of Lodz (2009-2016); START Award (2008) and Conferences Awards (2005, 2007) of Foundation for Polish Science, Polityka journal Awards for Young Scientists (2006), and Travel Grants of European Society of Hypertension (2007) and Heart Failure Association of ESC (2005, 2007).

His main area of scientific interests concerns hypertension aspects (risk stratification, prehypertension, new biomarkers, optimal level of BP – J-curve phenomenon, pharmacotherapy/combined therapy, prevention, complications), lipid disorders (risk stratification, new biomarkers, diagnosis, rare diseases), dyslipidemia therapy (statins, new drugs, combined treatment) and new drugs in CVD therapy.


Sunday 26 May 14:15

Efficacy & Safety of nutraceuticals

Nutritional and dietary approaches for personalised treatment


Sunday 26 May 14:15

Panel discussion: When & how to use nutraceuticals in primary prevention

Nutritional and dietary approaches for personalised treatment


Monday 27 May 13:15

The criticality of LDL goal attainment

Problems and solutions in lipid lowering therapy: how to optimise dyslipidaemia management


Monday 27 May 07:45

Nutraceuticals in clinical practice

NUTRACEUTICALS IN CONTROLLING LDL CHOLESTEROL


Monday 27 May 07:55

Closing remarks

NUTRACEUTICALS IN CONTROLLING LDL CHOLESTEROL